ScreenerHero

VCNX Vaccinex, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · vaccinex.com
1.000USD0.00%Mkt Cap: 2.68M $P/E: —

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.68M USD
Enterprise Value2.99M USD
Revenue (TTM)601.00K USD
Gross Profit-11.94M USD
Net Income (TTM)-18.63M USD
Revenue/Share0.29 USD
Last Price1.000 USD
Fiscal Year EndDec 2024
MR QuarterDec 2024
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.14
PEG—
EV/EBITDA-0.16
EV/Revenue4.98
P/S4.45
P/B-0.64
EPS (TTM)-8.88
EPS (Forward)-0.14
52W Range
0.310058% of range1.500
52W High1.500 USD
52W Low0.3100 USD
Profitability
Gross Margin0.00%
Oper. Margin-1590.14%
EBITDA Margin0.00%
Profit Margin-3100.50%
ROE748.95%
ROA-717.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.19M USD
CapEx (TTM)22.00K USD
FCF Margin-1920.74%
FCF Yield-431.27%
Net Debt-1.08M USD
Net Debt/EBITDA0.06
Balance Sheet
Debt/Equity-0.01
Current Ratio0.50
Quick Ratio0.38
Book Value/Sh-1.55 USD
Cash/Share0.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateFeb 20, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.68M
Float1.48M
Insiders11.41%
Institutions45.01%
Short Interest
Short Ratio0.6d
Short % Float3.23%
Short % Out.2.32%
Shares Short62.11K
Short (prev mo.)127.50K
Technical
SMA 501.025 (-2.4%)
SMA 2001.021 (-2.1%)
Beta0.68
S&P 52W Chg16.67%
Avg Vol (30d)1.38K
Avg Vol (10d)670
Technical Indicators
RSI (14)51.7
MACD0.0044
MACD Signal-0.0120
MACD Hist.+0.0164
BB Upper1.191 USD
BB Middle0.9366 USD
BB Lower0.6821 USD
BB Width54.33%
ATR (14)0.0952 USD
Vol Ratio (20d)0.16x